Cardiac Amyloidosis in a Patient Presenting with Symptoms of Heart Failure

Year 2021, Volume: 3 Issue: Supplement 1, 127 - 130, 07.03.2021

Sefa Erdi Ömür , Çağrı Zorlu

https://doi.org/10.46310/tjim.873267

Abstract

Cardiac amyloidosis (CA); It can be referred to as a progressive cardiomyopathy that occurs as a result of the accumulation of endogenous proteins in the form of amyloid fibrils, whose folding is disrupted in the kidney, liver, gastrointestinal system, soft tissue and heart. The course of the disease depends on the involvement of the organs and treatment options depending on the source of the protein. Immunoglobulin light chain (AL) amyloidosis and transtretin (TTR) amyloidosis are the most common CA types. While AL amyloidosis is more common in the heart and kidney, TTR amyloidosis is more common in the heart. Although CA is not considered a common disease, TTR amyloidosis is observed in approximately 15% of patients with heart failure with preserved ejection fraction and severe aortic stenosis. CA diagnosis; It can be placed by echocardiography (ECHO), magnetic resonance or nuclear scintigraphy methods. At the same time, genetic analysis, biopsy and histopathological tests are also useful for early diagnosis. After the diagnosis, antiplasma treatment or stopping the produced protein constitute the main lines of the treatment.

Keywords

amyloidosis, mitral valve regurgitation, heart failure

References

• 1. Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol 2000;130:88-98.
• 2. Gertz MA. Immunoglobulin light chain amyloidosis diagno- sis and treatment algorithm 2018. Blood Cancer J 2018;8:44.
• 3. Ruberg FL, Berk JL. Transthyretin(TTR) car- diac amyloidosis. Circulation 2012;126:1286- 300.
• 4. Cyrille NB, GoldsmithJ, AlvarezJ, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiacamyloidosis. Am JCardiol 2014;114: 1089-93.
• 5. Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light- Chain) Cardiac amyloidosis: a review of diagnosis and ther- apy. J Am Coll Cardiol 2016;68:1323–41.
• 6. Gertz MA, Kyle RA: Primary systemic amyloidosis-a diagnostic primer. Mayo Clin Proc 1989;64: 1505-9.
• 7. Murtagh, B, Hammill, SC, Gertz, MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005; 95:535.
• 8. Falk, RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112:2047.
• 9. Gertz MA, Lacy Mo, Dispenzieri A: Amyloidosis: Recognization, confirrnation, prognosis, and therapy. Mayo Clin Proc 1999;74: 490-5.
• 10. Fukuda N, Takeichi N, Soeki T: Cardiac amyloidosis with atrioventricular valve thickening and left atrial disfunction: a case report. J Cardiol 1 998;31 (Suppl): 123-29.
• 11. Reisinger J, Dubrey S, Lavalley M: Electrophysiological abnorrnalities in AL (primary) amyloidosis with cardiac involvement. J Arn Co ll Cardiol 1997;30:1046-51.
• 12. Skinner, M, Sanchorawala, V, Seldin, DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140:8.